Qiagen NV at Barclays Global Healthcare Conference Transcript
Good morning, everybody. Luke Sergott from Barclays to cover life sciences tools and diagnostics. With me I have the pleasure of meeting John Gilardi, IR and Roland Sackers, CFO of Qiagen. I guess, to kick it off, just kind of go over the high, real high points of the quarter. What you guys are seeing from a demand perspective and then how that's really progressing versus what you guys were expecting?
Sure. First of all, thanks for having us, and thanks for organizing, nice weather, we clearly deserve that. Yes, as you all know, we clearly finished the year '22 quite strong, not only the year, but also particularly in the fourth quarter, had a strong finish, particularly on the non-COVID growth rate, overall good growth rate. I think we were very pleased that all our [platforms] delivered on what we were expecting and adding to the market. And I know that some investors clearly had some concern about
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
